A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
Phase 2
36
about 2 years
18–85
11 sites in AR, CA, CO +7
What this study is about
This trial is testing whether a single dose of RABI-767, given by endoscopic ultrasound (EUS) guided peripancreatic injection, is safe and effective for people with predicted severe acute pancreatitis. Participants will be randomly assigned to receive either RABI-767 plus supportive care or just supportive care.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take RABI-767
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Change from Baseline in Clinical Chemistry Parameters, Change from Baseline in Hematology Parameters, Change from Baseline in Pulse Oximetry and Oxygen Delivery Measurements, Change from Baseline in Vital Signs, Number of Participants with Adverse Events, Number of Participants with Serious Adverse Events
Secondary: Change in Abdominal Pain Numeric Rating Score, Change in Computed Tomography Severity Index (CTSI) Score for Pancreatitis, Change in Modified Computed Tomography Severity Index (mCTSI) Score for Pancreatitis, Length of Stay in Intensive Care Unit, Re-hospitalization for acute pancreatitis or related complications